share_log

Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $16

Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $16

Needham维持对Recursion Pharmaceuticals买入评级,将价格目标下调至16美元
Benzinga ·  08/09 07:57  · 评级/大行评级

Needham analyst Gil Blum maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and lowers the price target from $17 to $16.

Needham分析师吉尔·布卢姆(Bil Blum)维持对Recursion Pharmaceuticals (纳斯达克:RXRX)的买入评级,并将目标价格从$17降至$16。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发